Kim, E., Park, S., Cho, D. S., Youn, J., Lee, H. S., Lee, H., . . . Baek, S. H. (2024). Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea. American Journal of Cardiovascular Drugs, 24(2), 313-324. https://doi.org/10.1007/s40256-024-00632-w
Chicago-referens (17:e uppl.)Kim, Eui-Soon, et al. "Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea." American Journal of Cardiovascular Drugs 24, no. 2 (2024): 313-324. https://doi.org/10.1007/s40256-024-00632-w.
MLA-referens (9:e uppl.)Kim, Eui-Soon, et al. "Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea." American Journal of Cardiovascular Drugs, vol. 24, no. 2, 2024, pp. 313-324, https://doi.org/10.1007/s40256-024-00632-w.
